BioSpace News Archive

Drug Development

Atlantic Healthcare reports results from Phase 1 trial of tablet for Crohn’s

Oral alicaforsen appears safe and well-tolerated

September 30, 2018
·
5 min read
DNAe Wins Inaugural 2018 Medtech Insight Top Innovator Award

DNAe was named ‘Most Innovative Team or Innovator of the Year’ at the inaugural 2018 Medtech Insight Awards.

September 30, 2018
·
5 min read
Deals

LGC acquires Berry & Associates

LGC has today announced a further strengthening of its nucleic acid chemistry (NAC) offering with the acquisition of Berry and Associates, premier supplier of specialty oligo reagents.

September 30, 2018
·
3 min read
Microbix to Present at Muskoka Capital Conference

Conference Introduces Growth Companies to Investor September 28-30, 2018

September 30, 2018
·
3 min read
Business

Johnson & Johnson Announces New Collaboration to Advance Novel Vaccine for MERS

New collaboration with Coalition for Epidemic Preparedness Innovations (CEPI) and The Jenner Institute is latest example of Johnson & Johnson’s ongoing commitment to global pandemic preparedness efforts

September 30, 2018
·
8 min read
Business

Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)

Salix Sales Force to Promote First FDA-Approved Drug for Thrombocytopenia in Chronic Liver Disease Patients Scheduled to Undergo a Procedure

September 30, 2018
·
12 min read
Business

National THL Biobank partners with BC Platforms’ Global network of biobanks

Accelerates sharing of genomic and health data from more than 150.000 subjects

September 30, 2018
·
3 min read
Major international FDA-led study confirms CellOPTIQ® High Content Assay as leading in vitro platform to assess cardiotoxicity in new drugs

Clyde Biosciences announced today that its proprietary CellOPTIQ® High Content Assay (HCA) outperformed other assay types in the global CiPA myocyte study designed to develop more accurate and comprehensive in vitro cardiac safety evaluation of new drugs.

September 30, 2018
·
3 min read
Deals

Akari Therapeutics Enters into a Securities Purchase Agreement for up to $20 Million with Aspire Capital Fund, LLC

Akari Therapeutics, Plc today announces that it has entered into a Securities Purchase Agreement (the “Agreement”) of up to $20 million with Aspire Capital Fund, LLC

September 30, 2018
·
6 min read
Drug Development

Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children

Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children

September 30, 2018
·
4 min read